The magnitude of decline in renal function that should be tolerated during intensive BP lowering and its association with risk of ESRD are unclear. To determine whether the acute declines in kidney function in the intensive BP lowering arm of two trials in CKD associated with higher risk of ESRD, we performed a retrospective study of 899 African American Study of Kidney Disease and Hypertension (AASK) and 761 Modification of Diet in Renal Disease (MDRD) Trial participants previously randomized to strict versus usual BP control. The predictor was the percentage decline in eGFR (,5%, 5% to ,20%, or $20%) between randomization and months 3 and 4 of the trial (time to achieve BP goals). ESRD was the outcome of interest. Compared with a ,5% eGFR decline in the usual BP arm, a 5% to ,20% eGFR decline during intensive BP lowering did not associate with a higher risk of ESRD in the AASK (adjusted hazard ratio [aHR], 1.19; 95% confidence interval [95% CI], 0.84 to 1.68) or the MDRD Trial (aHR, 1.08; 95% CI, 0.84 to 1.40). However, a 5% to ,20% eGFR decline in the usual BP arm associated with higher risk of ESRD in AASK (aHR, 1.83; 95% CI, 1.30 to 2.57) and MDRD Trial (aHR, 1.62; 95% CI, 1.25 to 2.11). A $20% eGFR decline associated with higher risk of ESRD in both strict and usual BP arms. Thus, acute eGFR declines $20% during intensive BP lowering identified a subset of patients at higher risk for adverse outcomes.
During the initiation of antihypertensive therapy, acute declines in renal function occur frequently and are thought to be related to reversible hemodynamic alterations. [1] [2] [3] [4] These "hemodynamic" effects of BP lowering have received particular attention in the setting of renin-angiotensin-aldosterone system (RAAS) inhibition. [5] [6] [7] [8] It has been suggested that an acute rise in serum creatinine of up to 30% (equivalent to a 27% decline in eGFR) 9 ,10 on initiating RAAS inhibitors is an acceptable tradeoff for the long-term benefits conferred by RAAS inhibition. 1, 11 Others have even suggested that the occurrence of an acute decline in renal function during the initiation of RAAS inhibition may be a harbinger of renoprotective success. 6, 12 In the recent Systolic Blood Pressure Intervention Trial (SPRINT), there was a higher prevalence of AKI among participants assigned to the intensive BP treatment arm. 19 In the Secondary Prevention of Small Subcortical Strokes Trial, participants in the intensive BP treatment arm experienced a more rapid decline in renal function within the first year of followup. 13 Despite the common recommendation that increases in serum creatinine of up to 30% in the first few months of therapy do not warrant discontinuation of RAAS inhibitors, 14 it is not clear whether there is a threshold of acute decline in renal function during intensive BP lowering that is associated with a higher long-term risk of ESRD. It is possible that these acute declines in renal function in the setting of intensive BP lowering may lead to a higher risk of ESRD due to either a higher predisposition for subsequent AKI events or development of fibrosis caused by chronic renal hypoperfusion. 15 The objective of this study was to examine the association between acute declines in renal function (measured as a percentage change in eGFR) and long-term risk of ESRD in two completed trials of intensive BP lowering in CKD, the African American Study of Kidney Disease and Hypertension (AASK) and the Modification of Diet in Renal Disease (MDRD) Trial, to determine whether data from these clinical trials support currently accepted practice for this common clinical problem.
RESULTS
The baseline characteristics of the 899 AASK participants and 761 MDRD participants included for study are shown in Table 1 and Supplemental Table 1 . Participants with larger acute declines in renal function had higher baseline mean arterial pressure (MAP), higher baseline proteinuria, and lower baseline eGFR in both the strict and usual BP arms (Table 1, Supplemental Table 1 ) in the AASK and the MDRD Trial. The AASK participants who were excluded from analysis due to missing creatinine or follow-up data were more likely to be women and had a higher baseline MAP (Supplemental Table 2A ). No differences in characteristics were noted between those included and excluded for analysis in the MDRD Trial (Supplemental Table 2B ).
A total of 341 ESRD events (176 in the usual BP arm) occurred in the AASK during median follow-up of 11.1 (interquartile range, 5.7-15.0) years. In the AASK, a small (,5%) decline in renal function in the strict BP arm was not associated with a statistically significantly different risk of ESRD compared with a small decline in renal function in the usual BP arm (Table 2) . Moderate declines (5% to ,20%) in renal function in the strict BP arm also were not associated with statistically significantly higher risk of ESRD (adjusted hazard ratio [HR], 1.19; 95% confidence interval [95% CI], 0.84 to 1.68). In contrast, a moderate decline in renal function among participants in the usual BP arm was associated with a near doubling of ESRD risk (adjusted HR, 1.83; 95% CI, 1.30 to 2.57). There was a statistically significant difference comparing the risk of ESRD in the strict (HR, 1.19) BP arm with the risk of ESRD in the usual (HR, 1.83) BP arm among participants who exhibited a 5% to ,20% decline in renal function (P=0.03). A large ($20%) decline in eGFR was associated with a higher long-term risk of ESRD in both the strict and usual BP arms in the AASK (Table 2) . After additional adjustment for the achieved MAP at month 3 in the AASK, our findings did not differ substantially.
When we changed the threshold to define a moderate decline in renal function to $15% (with moderate decline thus 5% to ,15%) in sensitivity analysis, the data were parallel to those of our primary analysis. The AASK participants assigned to strict BP control who had a 5% to ,15% decline in renal function did not have a statistically significantly higher long-term risk of ESRD (Table 3) . However, the AASK participants assigned to usual BP control with a 5% to ,15% decline in eGFR did have a statistically significantly higher risk of ESRD (Table 3) .
When we changed the threshold to define a moderate decline in renal function to $25% (with moderate decline thus 5% to ,25%) in sensitivity analysis, there was a statistically significantly higher risk of ESRD in the AASK participants assigned to strict BP control with a 5% to ,25% decline in renal function (adjusted HR, 1.45; 95% CI, 1.05 to 2.00) ( Table 3 ). This risk was not statistically significantly different (P=0.17) than the risk of ESRD in participants with a 5% to ,25% renal function decline in the usual BP arm (adjusted HR, 1.86; 95% CI, 1.34 to 2.57). A $25% decline in renal function was associated with higher risk of ESRD in both the strict and usual BP arms (Table 3) .
We derived similar results as those in our primary analysis when using measured GFR as the predictor of interest in the AASK. There was no statistically significant difference in risk of ESRD comparing those with a ,5% decline in renal function in the strict versus usual BP arm (HR, 0.94; 95% CI, 0.72 to 1.24). There was a statistically significantly higher risk of ESRD in the AASK participants assigned to usual BP control with a 5% to ,20% decline in renal function (adjusted HR, 1.73; 95% CI, 1.23 to 2.43) but not those with strict BP control (adjusted HR, 1.07; 95% CI, 0.78 to 1.48).
When we stratified our analysis by whether there was any reduction in proteinuria during intensive BP lowering, we found results that were overall consistent with our primary analysis. Among those with a 5% to ,20% decline in eGFR in the strict BP arm, the risk of ESRD was 1.19 (95% CI, 0.78 to 1.82) among those with any reduction in proteinuria (n=559) during the first 6 months of study and 1.61 (95% CI, 0.87 to 2.95) among those with an increase in proteinuria (n=340) compared with a ,5% eGFR decline in the usual BP arm. Among those with a 5% to ,20% decline in the usual BP arm, risk of ESRD was statistically significantly higher among those with both any reduction in proteinuria (HR, 1.94; 95% CI, 1.28 to 2.96) and an increase in proteinuria (HR, 4.96; 95% CI, 2.80 to 8.79) compared with those with a ,5% decline in the usual BP arm.
We tested for but did not find a statistically significant interaction between randomized assignment to different antihypertensive agents and percentage decline in eGFR category in the AASK. There was also no statistically significant interaction between percentage decline in eGFR category in the AASK and tertiles of baseline eGFR (all P.0.05). In sensitivity analysis, our results were overall similar when we limited our analysis to the duration of follow-up during the AASK Trial (Supplemental Table 3 ).
In the MDRD Trial, a total of 571 patients had ESRD (290 in the usual BP arm) during median follow-up of 5.9 (interquartile range, 3.3-11.5) years. A 5% to ,20% decline in renal function in the strict BP arm was not associated with a significantly higher risk of ESRD (adjusted HR, 1.08; 95% CI, 0.84 to 1.40) ( Table 2 ). However, a 5% to ,20% decline in renal function in the usual BP arm was associated with a higher risk of ESRD (adjusted HR, 1.62; 95% CI, 1.25 to 2.11). The risk of ESRD in the strict (HR, 1.08) versus usual (HR, 1.62) BP arm participants who exhibited a 5% to ,20% decline eGFR was statistically significantly different (P=0.003). A large decline in renal function ($20%) was associated with a higher risk of ESRD in both the strict and usual BP arms in the MDRD Trial (Table 2) .
DISCUSSION
In this study, we found that an acute decline in renal function of up to 20% during intensive BP lowering did not seem to be associated with a higher long-term risk of ESRD in two diverse CKD populations. However, large declines in renal function ($20%) were associated with a higher risk of ESRD. These findings were consistent across two separate cohorts. In contrast, any decline $5% in the usual BP arm was associated with a higher risk of ESRD, which we postulate is likely related to natural progression of kidney disease, versus the declines in eGFR observed in the strict BP arms, which may be partially hemodynamic and may not be reflective of permanent structural changes in renal parenchyma.
Few studies have examined the association between acute declines in renal function during intensive BP lowering and hard outcomes, such as the risk of ESRD, due to the relatively low number of ESRD events that occur during the duration of most clinical trials. 1, 6, 11, 12 Instead, investigation has focused mainly on the protective effect of BP control on the rate of CKD progression using the slope of renal function decline as the end point of interest. 1, 6, 12, 16, 17 We believe that our study offers novel insight into the implications of short-term declines in renal function that may occur during intensive BP lowering.
In light of the recent results from the SPRINT, intensive BP lowering may become more common in clinical practice. 18, 19 Our prior long-term follow-up study of the AASK and the MDRD Trial participants showed that, overall, strict BP control did not lead to a higher risk of ESRD, which is reassuring. 20, 21 Our study differs from our prior study, because our goal was to identify the subset of patients who may be at higher risk for ESRD on the basis of the response of the patient's renal function to intensive BP lowering. Our data provide support that declines in renal function up to 20% during intensive BP lowering would not be a reason to relax the intended BP target. However, we do suggest that cautious follow-up may be warranted for the subset of patients who exhibit a 20% or greater decline in renal function during intensive BP lowering. We are, however, unable to determine whether relaxing BP targets in patients who experience a $20% decline in renal function during strict BP control would mitigate the higher risk of ESRD seen in our study given the observational nature of our data.
Of note, we did not find any effect modification by assigned antihypertensive agent (angiotensin-converting enzyme [ACE] inhibition versus calcium channel blocker or b-blocker) on the association between percentage decline in renal function and long-term risk of ESRD in the AASK, although our analysis may be limited in power. Some experts have suggested that a 30% rise in serum creatinine (corresponding to a 27% reduction in eGFR) 10 during initiation of RAAS inhibition should be tolerated because of the long-term benefits associated with RAAS inhibition. 11, 22, 23 On the basis of our sensitivity analysis, such declines in the setting of intensive BP lowering with or without RAAS inhibitor use would be associated with a higher risk of ESRD. The strengths of our study include the large number of ESRD events and the availability of nearly two decades of follow-up in the AASK and the MDRD Trial participants. Furthermore, our findings were similar in two independent heterogeneous trials of patients with CKD. However, it is important to recognize that our study is post hoc and observational and that it does not preserve the original randomization schema of the AASK and the MDRD Trial. Our results may not apply to persons with CKD attributed to diabetes or persons without CKD. In addition, we have limited data on the occurrence of AKI during the AASK and the MDRD Trial and its potential contribution to risk of ESRD during long-term follow-up.
In conclusion, we showed that a 5% to ,20% decline in renal function in the setting of strict BP control (to target BP levels in the 125/75 mmHg range) was associated with a lower future risk of ESRD compared with similar declines in renal function under usual BP control (to target BP levels in the 140/ 90 mmHg range). A $20% decline in renal function was associated with higher risk of ESRD in both strict and usual BP control strategies. These results suggest that a ,20% decline in renal function can be tolerated during intensive BP lowering. A $20% decline in renal function during intensive BP lowering identifies a subset of patients at higher risk for ESRD. Further studies are needed to assess the long-term risk-tobenefit ratio of continuing intensive BP lowering when large declines in renal function occur.
CONCISE METHODS

Study Populations
The AASK was a large 233 factorial, randomized, controlled trial that assessed the effect of strict BP control and different antihypertensive agents on the progression of CKD in black participants with hypertensive CKD. Between 1995 and 2001, 1094 participants between 18 and 70 years of age with GFR=20-65 ml/min per 1.73 m 2 were randomized to either strict (MAP#92 mmHg) or usual (MAP=102-107 mmHg) BP control. Patients were also simultaneously randomized to an ACE inhibitor (ramipril), b-blocker (metoprolol), or calcium channel blocker (amlodipine) as their first antihypertensive agent in 2:2:1 allocation. At trial closure, 691 participants (87% of eligible participants) who had not developed ESRD or died continued in the cohort phase of the study, which began in 2002 and ended in 2007. [24] [25] [26] All AASK cohort participants were switched to an ACE inhibitor as first-line therapy or an angiotensin receptor blocker if an ACE inhibitor could not be tolerated. During the AASK cohort study, all participants were treated to a BP target of ,140/90 mmHg, and this target was changed to ,130/80 mmHg after 2004. 25, 27 We considered the AASK the primary cohort of interest in this study, because it was the larger of the two trials of interest, was more contemporary, and randomized patients to alternative antihypertensive agents and therefore, allowed for examination of effect modification by assigned antihypertensive agent. We used the MDRD Trial as a secondary cohort of interest, primarily to validate the major findings in our AASK analyses. Table 3 . Sensitivity analyses using alternative categories of percentage decline in renal function in the AASK participants using a threshold of decline of 15% or 25% The MDRD Trial randomized 840 participants with nondiabetic CKD between 18 and 70 years of age with GFR=13-55 ml/min per 1.73 m 2 to either strict (MAP,92 or ,98 mmHg depending on age)
or usual (MAP,107 or ,113 mmHg) BP control (and dietary protein restriction in a factorial design) between 1989 and 1993. 16 ACE inhibitors were encouraged as first-line antihypertensive agents. 16 
Predictor of Interest
The main predictor of interest was the acute change in eGFR obtained over the period of time that reflects active titration of antihypertensive regimens to achieve MAP goals in the AASK and the MDRD Trial. We chose to use eGFR as the predictor of interest (as opposed to measured GFR) to enhance the clinical applicability of our study results, because measured GFR would not be available in most clinical settings. In addition, we have previously shown that changes in eGFR were more strongly associated with risk of ESRD than changes in measured GFR in patients with CKD. 28 Changes in eGFR correspond closely to changes in serum creatinine-on which currently accepted clinical practice guidelines are based-but have the added benefit of incorporating other demographic and clinical characteristics that may affect serum creatinine outside of GFR.
In the AASK, we examined serum creatinine values obtained at baseline and follow-up visit 3 (approximately month 3 after randomization). In the MDRD Trial, we examined serum creatinine values obtained at baseline and follow-up visit 4 (approximately month 4 after randomization). These central laboratory serum creatinine values were used to determine eGFR using the 2009 creatinine-based Chronic Kidney Disease Epidemiology Collaboration equation. 10 Change in renal function was then determined as the percentage change in eGFR between baseline and visit 3 in the AASK and between baseline and visit 4 in the MDRD Trial. We then categorized these changes in renal function as ,5% (small), 5% to ,20% (moderate), or $20% (large) decline and separated patients into groups on the basis of these changes and according to assignment to either strict or usual BP control. These cutoffs were chosen on the basis of the distribution of the percentage change in renal function in the AASK (a 20% decline in renal function represented 1 SD of percentage change in renal function above the mean) and because we judged that this cutoff represented a clinically meaningful change in renal function over a 3-to 4-month period. 29 The mean change in eGFR between randomization and month 3 was 2% in the AASK participants, and therefore, we considered a ,5% decline to likely represent clinically stable renal function (allowing for potential noise in creatinine measurements) and chose 5% as the cutoff for the reference group.
The primary predictor of interest was thus a six-level categorical variable that incorporated the magnitude of the renal function decline and BP goal assignment during the trial (,5% decline in the usual BP arm [reference], ,5% decline in the strict BP arm, 5% to ,20% decline in the usual BP arm, 5% to ,20% decline in the strict BP arm, $20% decline in the usual BP arm, and $20% decline in the strict BP arm).
In sensitivity analysis, we also used 15% and 25% (versus 20%) thresholds to recategorize our predictor of interest and repeated our analyses in the AASK participants. In addition, we repeated our analysis using changes in renal function using iothalamate-measured GFR.
Outcome Ascertainment
The primary outcome of interest was the development of ESRD. To extend ascertainment of ESRD beyond the parent AASK, we performed linkage of the AASK participants with the US Renal Data System (USRDS; the national United States ESRD registry) through June 30, 2012 as previously described. 20 We performed linkage of former MDRD Trial participants to the USRDS through December 31, 2010 as previously described. 21 We defined ESRD as receipt of chronic dialysis or kidney transplant. Long-term ascertainment of vital status through national death indices in the AASK and the MDRD Trial participants has been previously described. 20, 21 Participants were censored from our analyses if they died or administratively censored on June 30, 2012 in the AASK and December 31, 2010 in the MDRD Trial.
In the AASK, patients without identifiers available for linkage to external administrative databases (n=27) were excluded from analyses, so that the total number of participants with available long-term ESRD and death follow-up was 1067 (98% of original AASK enrollees). An additional 168 AASK participants were excluded from our study due to missing central laboratory serum creatinine (n=151) or death (n=17) at or before visit 3.
Long-term ascertainment of ESRD and death was complete for all 840 MDRD Trial participants, but we excluded 77 participants from the MDRD Trial analyses due to missing creatinine at visit 4, and two additional patients were excluded who died before visit 4.
Statistical Analyses
We assessed the risk for the primary outcome of interest, ESRD, according to our six-level primary predictor using unadjusted Cox models starting at the time of randomization in the AASK. We subsequently adjusted these models for baseline age, sex, heart disease (defined by a combination of self-report, chart review, and baseline electrocardiogram reading), MAP, eGFR (categorized by standard CKD stages due to non-normality), proteinuria (categorized as above or below the median proteinuria level due to non-normality), and baseline ACE inhibitor use (yes/no). We also tested for differences in the risk of ESRD within each category of renal function decline by BP goal assignment. In post hoc exploratory analysis, we further adjusted these models by achieved MAP at month 3 to determine whether the association between categories of declines in renal function and risk of ESRD would remain robust.
To determine whether risk of ESRD would differ in those who experienced a reduction in proteinuria during intensive BP lowering, we performed additional analysis stratifying our adjusted Cox models in the AASK by the presence or absence of a reduction in proteinuria between baseline visit and visit 6 (which was the first assessment of proteinuria available after randomization in the AASK). In sensitivity analysis, we limited our follow-up duration to the AASK only, which ended in September of 2001, and repeated our analyses.
In addition, to determine whether the risk of ESRD would differ by the degree of renal impairment at baseline, we tested for the presence of interaction between categories of decline in renal function in the AASK and tertiles of baseline eGFR. We also tested for the presence of interaction between random assignment to ACE inhibitor (versus other antihypertensive agents) and categories of percentage decline in renal function in the AASK.
Next, we repeated our primary analysis among the MDRD Trial participants using both unadjusted and adjusted Cox models. Our adjusted models in the MDRD Trial analyses included the same covariates as in models for the AASK, except with the additional adjustment for race (categorized as white, black, or other).
We used Stata 14 (StataCorp LP) for all statistical analyses, and our main analyses were verified by a separate analyst using SAS, version 9 (SAS Institute). Institutional review board approval was obtained at the University of California, San Francisco, and deidentified National Institute of Diabetes and Digestive and Kidney Diseases repository datasets were used for analyses. The funding source did not have any role in manuscript preparation. This manuscript does not necessarily reflect the opinions or views of the AASK or the MDRD Trial and cohort studies, the NIDDK Central Repositories, or NIDDK grants 000182, UL1TR000124, and P30AG021684. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. The interpretation and reporting of the data presented here are the responsibility of the authors and in no way should be seen as an official policy or interpretation of the US Government.
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